Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat - BioPharma APAC

Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat BioPharma APAC Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat Cision News Endometriosis and fibroids: Expert explains advances giving women less invasive treatment options Florida Hospital News and Healthcare Report Essentia offers new fibroid treatment in Fargo InForum Essentia Health-Fargo Offers New Minimally Invasive Uterine Fibroid Procedure Midwest Medical